Invest in the future of drug discovery
We’re proud to be supported by some of the world’s leading investors who have a strong track record of working with successful, high-growth companies.
We’ve raised over $70 million to date and are grateful for the continued support of our partners – from seed round to Series B and beyond.
We are always keen to hear from companies who share our vision to use AI to accelerate the discovery and development of rare disease treatments at scale. Please get in touch to explore ways of working together.Contact us
We believe that the new paradigm in drug discovery will emerge at the intersection of technology, data, and biology, and we’re confident that Healx’s team is paving the way to a new gold standard in rare disease treatment discovery.
The future of medicine will focus on what is different about everyone, personalising treatment and taking the individual into context. Healx’s Healnet platform, at the forefront of this shift, is already delivering value and Balderton is excited to have the opportunity to be part of the company’s journey.
Trina Van Pelt
AI coupled with compute can disrupt and dramatically speed the drug discovery process, and Healx owns the most comprehensive knowledge graph of rare diseases. We’re excited to support this experienced leadership team and provide Intel technology to optimize deep learning workloads, improve performance and lower costs.
It’s a pleasure to have been part of Healx since the very beginning. The way they’ve scaled the team, the tech and the number of rare disease projects worked on over the years has been astonishing to watch. If ever proof was needed of the power of technology for societal good - this is it.
Dr Ronjon Nag
The way Healx blends the latest AI technology with exceptional drug discovery expertise and patient insights has not only disrupted the traditional approach to drug discovery - it’s the secret ingredient to their success to-date in quickly and effectively finding potential treatments for rare diseases.